• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Johnson & Johnson beats The Street in Q2, lowers full-year guidance

Johnson & Johnson beats The Street in Q2, lowers full-year guidance

July 19, 2022 By Sean Whooley

johnson & johnsonJohnson & Johnson (NYSE:JNJ) shares were up before hours on second-quarter results that came in ahead of the consensus forecast.

The New Brunswick, New Jersey-based company posted profits of $4.8 billion, or $1.80 per share, on sales of $24 billion for the quarter ended June 2022, for a 23.3% bottom-line slide on sales growth of 3%.

Adjusted to exclude one-time items, earnings per share were $2.59, 2¢ ahead of Wall Street, where analysts were looking for sales of $23.8 billion.

Johnson & Johnson MedTech, formerly the company’s medical devices segment, experienced a 1.1% decrease in sales, pulling in nearly $6.9 billion in revenues for the three-month period. The company’s adjusted operational sales grew 3.4%, driven primarily by contact lenses and surgical vision products, as well as electrophysiology products, according to a news release.

Growth in the MedTech segment was “partially offset” by COVID-19-related mobility restrictions in certain regions.

The company’s consumer health segment also saw a sales dip (1.3%), while the pharmaceutical segment brought in nearly double the MedTech business’ revenues at $13.3 billion. That represented year-over-year growth of 6.7%, driven by a number of therapeutics, including Darzalex, Stelara, Erleada and Tremfya. The company’s Janssen COVID-19 vaccine also contributed to growth.

“Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company’s market leadership in the midst of macroeconomic challenges,” CEO Joaquin Duato said in the release. “I am continually energized by the focus and passion of my Johnson & Johnson colleagues and their dedication toward delivering transformative healthcare solutions to patients and consumers around the world.”

The company said it now expects to log adjusted EPS of between $10 and $10.10, compared with a range of $10.15 to $10.35 previously. The company reduced its prior sales guidance for between $93.3 billion and $94.3 billion, having previously set expectations for between $94.8 billion and $95.8 billion.

Truist analysts described J&J’s results as “less bad than feared.” They noted that J&J management said inflationary pressures are expected to persist into next year, but the pressures appear to be stabilizing both for supply chain and costs.

JNJ shares were down slightly at $172.52 apiece by midday trading today. MassDevice’s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up 1%.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Johnson & Johnson, Johnson & Johnson MedTech

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy